Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company developing a new class of RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs™), announced that it will deliver late-breaking oral and poster presentations at the 30th Annual International Congress of the World Muscle Society (WMS), taking place October 7–11, 2025, in Vienna, Austria.
The presentations will expand on positive results shared in September 2025 showing reversal of disease progression and significant functional improvement in patients with Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping (DMD44) treated for one year with delpacibart zotadirsen (del-zota) in the Phase 1/2 EXPLORE44® and Phase 2 EXPLORE44-OLE™ studies. Del-zota remains an investigational therapy and has not yet been approved by the FDA.
Key WMS 2025 Presentations
- Oral Presentation: Delpacibart zotadirsen (del-zota) showed trends toward improvement in functional and patient-reported outcomes in DMD44
Speaker: Dr. Kevin M. Flanigan, Nationwide Children’s Hospital
Date/Time: October 11, 2025, 12:33–12:45 p.m. CET - Poster Presentation (674P): Delpacibart Zotadirsen (Del-zota) Increased Dystrophin and Improved Muscle Integrity Markers Regardless of Ambulatory Status in Individuals with DMD44
Presenter: Dr. Aravindhan Veerapandiyan, University of Arkansas for Medical Sciences & Arkansas Children's Hospital
Date/Time: October 8, 2025, 2:30–3:30 p.m. CET
About Avidity Biosciences
Avidity Biosciences aims to transform RNA therapeutics with its AOC™ platform, which merges monoclonal antibody precision with oligonucleotide-based therapies to target diseases previously unreachable by RNA technologies. The company is advancing clinical programs in:
- Myotonic dystrophy type 1 (DM1)
- Duchenne muscular dystrophy (DMD)
- Facioscapulohumeral muscular dystrophy (FSHD)
Additionally, Avidity is expanding into rare genetic cardiomyopathies and developing programs in cardiology and immunology through strategic collaborations.
